However, the results regarding the benefit of adding anti-PD-1/PD-L1 therapy to chemotherapy in patients with advanced ESCC exhibiting low PD-L1 expression levels have been inconsistent [30, 31]. Here, CD274 is linked to esophageal squamous cell carcinoma.